Objective To investigate the influence of Baicalin and telbivudine on chronic hepatitis B cirrhosis and early serum indexes of liver fibrosis. Methods 64 patients (treatment group) were treated with baicalin and telbivudine. 62 patients (control group) were treated with telbivudine. The liver function, hepatitis B virus markers (HBVM), HBV DNA, liver fibrosis markers including hyaluronic acid (HA), laminin (LN), DI procollagen (PC IE), IV collagen (PC IV ) were observed. Results ALT normalization rate, HBVDNA and HBeAg negative conversion rate and anti-Hbe seroconversion rate of the treatment group after treatment were significantly higher than that before treatment (P<0. 05 or P <0. 01). HA? LN. PC Ⅲ of the treatment group after treatment was a significantly different from that of the control group (P<0. 05 or P<0. 01). Conclusion Baicalin and telbivudine has good anti-virus, anti-liver fibrosis effect.%目的 探讨黄芩苷联合替比夫定对慢性乙型肝炎(CHB)和早期肝硬化(HC)血清肝纤维化指标的影响.方法 采用随机分组法分为治疗组和对照组.治疗组64例患者服用黄芩苷,剂量为2粒/次,口服,每日3次,替比夫定600mg,每日1次；对照组62例替比夫定600mg,每日1次,两组疗程均为12个月.治疗前后定期检测血常规、肝功能、乙肝病毒标志物(HBVm)、HBV DNA,治疗前后各检测1次血清肝纤维化指标,包括透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)和Ⅳ型胶原(PCⅣ).结果 治疗前各组肝功能各指标间的差异无显著性,治疗后治疗组的ALT复常率、HBVDNA和HBeAg阴转率及抗-HBe阳转率均明显高于对照组(P＜0.05或P＜0.01).治疗组的HA、LN、PCⅢ于治疗后与时照组比较差异显著(P＜0.05或P＜0.01).结论 黄芩苷与替比夫定联合具有较好的抗病毒、抗肝纤维化效果.
展开▼
